Supercharged immune cells take on Hard-to-Treat lymphoma
NCT ID NCT04664179
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new type of immune cell therapy for patients with EBV-positive Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard treatments. The researchers add a gene called C7R to the patient's own T cells to help them survive longer in the body, potentially improving their ability to kill cancer cells. The study aims to find the safest dose and see if the cells can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- C7R-modified EBV-specific T cells
- What this could lead to
- If it works, this could offer a new treatment option for patients with EBV-positive lymphoma that has not responded to standard therapies.
- What could go wrong
- This is a very early phase 1 trial with only 52 participants, so it is too soon to know if the approach is safe or effective. There are risks of serious side effects from the modified T cells.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 52 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2022
- Expected to finish
-
Nov 2042
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
1. INCLUSION CRITERIA AT TIME OF PROCUREMENT 1. Any patient, regardless of age or sex, with EBV-positive Hodgkin's or non Hodgkin's Lymphoma, (regardless of the histological subtype) or EBV (associated)- T/NK-lymphoproliferative disease who may subsequently be eligible for the treatment component 2. EBV positive tumor (can be pending) 3. Weighs at least 10 kg 4. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given a copy of informed consent. 2. INCLUSION CRITERIA AT TIME OF INFUSION 1\) Any patient regardless of age or sex, with diagnosis of either 1. EBV positive Hodgkin's lymphoma 2. EBV positive non-Hodgkin's Lymphoma (regardless of histologic subtype) 3. EBV (associated)-T/NK-lymphoproliferative disease AND either A) In first or subsequent relapse or with persistent active disease despite therapy; OR B) With active disease if immunosuppressive chemotherapy is contraindicated as determined by the study PI, in consultation with the primary provider as needed, e.g. patients who develop Hodgkin's disease after solid organ transplantation or if the lymphoma is a second malignancy, e.g. a Richter's transformation of CLL. 2\) EBV positive tumor confirmed by pathology 3\) Patients with life expectancy ≥ 6 weeks 4\) Patients with bilirubin ≤ 3x upper limit of normal, AST ≤ 3x upper limit of normal, creatinine ≤ 2x upper limit of normal for age and Hgb ≥ 7.0 (may be a transfused value) 5\) Pulse oximetry of \>90% on room air 6\) Patients should have been off other investigational therapy for 4 weeks prior to entry in this study. 7\) Patients with a Karnofsky/Lansky score of ≥ 50 8\) Informed consent explained to, understood and signed by patient/guardian. Patient/guardian given a copy of informed consent. 3. EXCLUSION CRITERIA AT TIME OF PROCUREMENT 1\. Known pregnancy or actively breastfeeding (pregnancy test is not required at the time of procurement). 4. EXCLUSION CRITERIA AT TIME OF INFUSION 1. Pregnant or breastfeeding 2. Active and uncontrolled bacterial, viral or fungal infection 3. Current use of systemic corticosteroids (prednisone equivalent \>0.5 mg/kg/day) 4. Bulky disease resulting in airway obstruction or risk for airway obstruction with further enlargement.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV related non-Hodgkin's lymphoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
4 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Baylor St. Luke's Medical Center
NOT_YET_RECRUITINGHouston, Texas, 77054, United States
-
Harris Health System - Ben Taub General Hospital/Smith Clinic
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
-
Houston Methodist Hospital
RECRUITINGHouston, Texas, 77030, United States
-
Texas Children's Hospital
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.